Search

everythinglearnresearchcommunity

for

Search:↓

Some medications can cause hair loss, but stopping the drug usually leads to recovery within 3 months.

Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.

Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.

Cetuximab can cause eyelash growth, which is rare but manageable.

Frontal Fibrosing Alopecia's cause is unclear, affects mainly postmenopausal women, and current treatments focus on stopping hair loss rather than regrowth.

Targeted cancer therapies can cause skin side effects, which should be treated early to help patients' quality of life and treatment adherence.

Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.

Some drugs, especially biologics, can cause skin reactions that look like other skin diseases, and stopping the drug usually helps clear up these reactions.

Chemotherapy and radiotherapy can cause skin side effects like rashes, hair loss, and nail changes, which are usually managed with conservative treatments.

NF-κB signaling is crucial in many diseases and can be targeted for new treatments.

New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.

The document concludes that changes in eyelashes and eyelid skin can indicate various local and systemic diseases.

ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.

New treatments for advanced skin cancer are improving patient outcomes, but drug resistance and finding the right treatment combinations are still big challenges.

Epithelial-mesenchymal interactions control hair growth cycles through specific molecular signals.

Some synthetic carbohydrate receptors, especially compounds 3 and 15, show strong potential for treating Zika virus.

The document concludes that individualized treatment for malignant epithelial tumors is necessary and more research on metastatic squamous cell carcinoma treatments is needed.

The nucleus is key in controlling skin growth and repair by coordinating signals, gene regulators, and epigenetic changes.

The document tests knowledge and decision-making in hematology through multiple-choice questions.

The document provides 70 multiple choice questions to improve haematology skills.

Understanding drug interactions, side effects, and patient-specific factors is crucial for effective dermatological care.

The document highlights various patents for new compounds with potential treatments for multiple diseases, including cancer, hormonal disorders, and diabetes.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

Cyclosporine-A can cause excessive hair growth, which usually stops after discontinuing the drug.

The document concludes that understanding genetic mutations in the PI3K-AKT-mTOR pathway can lead to better diagnosis and treatment for certain genetic skin disorders.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

A protein called IL-36γ causes skin side effects from certain cancer treatments when combined with a common skin bacteria.

Blocking YAP/TAZ could be a new way to treat skin cancer.

Women with Polycystic Ovary Syndrome (PCOS) have a higher risk of developing type 2 diabetes due to insulin resistance.